News

Latest news

19th October 2023

Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission

Read more
19th October 2023

Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome

Read more
20th September 2023

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

Read more
19th September 2023

Sequana Medical announces H1 2023 results and provides business update

Read more
19th September 2023

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke

Read more
19th September 2023

Ann Meulemans and AbolerIS Pharma is featured in De Tijd newspaper

Read more
5th September 2023

ACTIMIS post-hoc results on imaging stroke data using Artificial Intelligence reinforces glenzocimab mode of action in stroke patients

Read more
21st August 2023

Newton Biocapital Featured on Global University Venturing (GUV)

Read more
25th July 2023

Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

Read more